Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

ment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... at Home now provides in-home caregivers who have been certified ... nursing, rehab therapy, caregiver, and hospice services to San Francisco ... ... Creek, CA (PRWEB) December 14, 2009 -- Professional HealthCare at ... home health care, including nursing, rehab, personal caregiver and hospice ...
(Date:12/14/2009)... Conkling of Moraga, CA, retired Senior Vice President of ... Chair of the Board of Trustees of the American Foundation ... to which Helen Keller devoted more than 40 years ... in San Francisco, Dallas, Atlanta, Washington, ... possibilities for people with vision loss. ,, "As we ...
(Date:12/14/2009)... -- Josie Raper, a 29 year-old mother from Phoenix who ... the help of the Dr. Siegal,s COOKIE DIET® six-cookies-a-day weight-loss ... Club segment on NBC,s Today Show. The Joy Fit Club ... a month and salutes those who have lost at least ... kept it off for two years. ,, "The first time ...
(Date:12/14/2009)... Dec. 14 Anthem Blue Cross announced ... intends to award Anthem the Tri-County Commercial contract renewal ... Kings and Madera Counties. This award is the second ... country this year. ,, "The award of this contract ... to deliver on the promise made to residents in ...
(Date:12/14/2009)... Dec. 14, 2009 Only about one in 2,000 ... Johnnie Wilcox was one of the unfortunate few. , Ms. ... early on, and even those problems were mistaken for blocked ... the right side of my nose," recalled the resident of ... of Texas, Hill Country. "I felt a fullness, but I ...
Breaking Medicine News(10 mins):Health News:Caregivers with Professional HealthCare at Home Now Certified by the Alzheimer's Association 2Health News:The American Foundation for the Blind Welcomes New Board Chair, Concetta F. Conkling 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:Anthem Blue Cross Wins Third Largest Medicaid Managed Care Contract Renewal in the Country 2Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2
... A group of mental health experts announced that the term ... scientific authority//, is vague and stigmatizing. ,"It is ... of social psychiatry at the University of Central England in ... are not the results of the illness but may be ...
... with serious flaws according to federal investigators which ... ,The New York Times reported that the computer ... the databank of the Centers for Medicare and ... nursing homes, insurance companies, health plans and other ...
... get uncomfortable after a heavy meal here is a piece ... that eating 6-8 walnuts (approx.40g) after a rich fatty meal, ... in the walls of arteries after a highly fatty meal. ... 17 issue of the Journal of the American College of ...
... of women who under go lumpectomy feel that the ... way// their breasts look, a recent survey has revealed. ... (ASPS) Plastic Surgery 2006 conference in San Francisco was ... that the majority of unhappy lumpectomy patients would explore ...
... Chicago: This piece of news challenges parenting stereotypes; Today’s ... number of computer games// they play, and the many talents ... and overriding ambition to churn out ‘super-kids’ , often smother ... in the form of gadgets , gizmos , play stations, ...
... foreign woman suffering a heart ailment, masquerading with a Chinese ... has got herself treated in a hospital in// Auckland to ... ,While outlining the apparent difficulties in sifting the ... Brown explained how the 66 year old patient was ineligible ...
Other Medicine News:Health News:‘Schizophrenia’ term ought to be abolish 2Health News:Walnuts May Help Fight Fat and Keep Arteries Supple 2
(Date:12/14/2009)... -- Travelers of Interstate 70 west of Indianapolis will ... more colorful when 10 multicolored art forms are installed ... going home , will eventually include 34 total pieces ... at Herron School of Art and Design, through the ... ,, Eli Lilly and Company (NYSE: LLY ...
(Date:12/14/2009)... Pa., Dec. 14 CPG International, ... engineered building products, introduces VYCOM, a rebranded ... the previous VYCOM Corporation and Scranton Products ... wholly recognized business unit within CPG International, ... Products Commercial. The VYCOM business unit has ...
(Date:12/14/2009)... Pharmaceutical Inc. (OTC Bulletin Board: OHRP) announced today ... in Irvine, CA, with offices also in New ... relations and corporate communications. Ohr Pharmaceutical is ... advanced drugs for underserved therapeutic needs. The Company ... markets: OHR/AVR118 for the treatment of Cachexia and ...
Breaking Medicine Technology:Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 1Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 1Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 3Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 4Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 5Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 1Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 2
... and REBETOL(R) will be the only available hepatitis C therapy, approved ... ... approval, KENILWORTH, ... that the Committee for Medicinal,Products for Human Use (CHMP) of the ...
... Sept. 24 Knopp Neurosciences Inc. ("Knopp"),today ... clinical trial of KNS-760704, a,small molecule therapy ... sclerosis (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ... ascending,dose study in healthy volunteers is being ...
Other Medicine Technology:European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 2European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 3European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 4European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 5European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 6European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 7European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 8Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 2Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: